The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast Cancer

Lucchetti, Chiara; Caligiuri, Isabella; Toffoli, Giuseppe; Giordano, Antonio; Rizzolio, Flavio
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
In hormone receptor-positive breast cancers, most tumors in the early stages of development depend on the activity of the estrogen receptor and its ligand, estradiol. Anti-estrogens, such as tamoxifen, have been used as the first line of therapy for over three decades due to the fact that they elicit cell cycle arrest. Unfortunately, after an initial period, most cells become resistant to hormonal therapy. Peptidylprolyl isomerase 1 (Pin1), a protein overexpressed in many tumor types including breast, has been demonstrated to modulate ERalpha activity and is involved in resistance to hormonal therapy. Here we show a new mechanism through which CDK2 drives an ERalpha-Pin1 interaction under hormone- and growth factor-free conditions. The PI3K/AKT pathway is necessary to activate CDK2, which phosphorylates ERalphaSer294, and mediates the binding between Pin1 and ERalpha. Site-directed mutagenesis demonstrated that ERalphaSer294 is essential for Pin1-ERalpha interaction and modulates ERalpha phosphorylation on Ser118 and Ser167, dimerization and activity. These results open up new drug treatment opportunities for breast cancer patients who are resistant to anti-estrogen therapy.


Related Articles

  • Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Xin Pan; Tao Zhou; Yan-Hong Tai; Chenguang Wang; Jie Zhao; Yuan Cao; Yuan Chen; Pei-Jing Zhang; Ming Yu; Cheng Zhen; Rui Mu; Zhao-Fang Bai; Hui-Yan Li; Ai-Ling Li; Bing Liang; Zhao Jian; Wei-Na Zhang; Jiang-Hong Man; Yan-Fei Gao; Wei-Li Gong // Nature Medicine;Jun2011, Vol. 17 Issue 6, p708 

    Endocrine resistance is a major obstacle to hormonal therapy for breast cancers. Although reduced expression of estrogen receptor-α (ER-α) is a known contributing factor to endocrine resistance, the mechanism of ER-α downregulation in endocrine resistance is still not fully understood....

  • Combination Treatment of Tamoxifen with Risperidone in Breast Cancer. Yeh, Wei-Lan; Lin, Hui-Yi; Wu, Hung-Ming; Chen, Dar-Ren // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the...

  • Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Taneja, Pankaj; Maglic, Dejan; Kai, Fumitake; Zhu, Sinan; Kendig, Robert D.; Fry, Elizabeth A.; Inoue, Kazushi // Clinical Medicine Insights: Oncology;2010, Issue 4, p15 

    The use of biomarkers ensures breast cancer patients receive optimal treatment. Established biomarkers such as estrogen receptor (ER) and progesterone receptor (PR) have been playing significant roles in the selection and management of patients for endocrine therapy. HER2 is a strong predictor...

  • Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Milani, Monica; Jha, Gautam; Potter, David A. // Clinical Medicine: Therapeutics;2009, Issue 1, p141 

    The majority of breast cancers express the estrogen receptor and depend on estradiol (E2) for their growth. Hormonal therapy aims at depriving estrogen signaling either by using selective estrogen receptor modulators (SERM)-that interfere with the binding of E2 to its receptor (ER)-or aromatase...

  • CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Iorns, Elizabeth; Martens-de Kemp, Sanne R.; Lord, Christopher J.; Ashworth, Alan // Carcinogenesis;Oct2009, Vol. 30 Issue 10, p1696 

    Endocrine therapies, which inhibit estrogen receptor (ER)α signaling, are the most common and effective treatment for ERα-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The cyclin-dependent kinase family member CRK7 (aka...

  • Repression of Estrogen Receptor alpha by CDK11p58 Through Promoting its Ubiquitin—Proteasome Degradation. Yanlin Wang; Hongliang Zong; Yayun Chi; Yi Hong; Yanzhong Yang; Weiying Zou; Xiaojing Yun; Jianxin Gu // Journal of Biochemistry;Mar2009, Vol. 145 Issue 3, p331 

    Estrogen receptor α (ERα) is a ligand-dependent transcription factor that mediates physiological responses to 17β-estradiol (E2). These responses of cells to estrogen are regulated in part by degradation of ERα. In this report, we found that CDK11p58 repressed ERα transcriptional...

  • Fulvestrant 500 mg in the Treatment of Advanced Breast Cancer. Robertson, John F. R. // European Journal of Clinical & Medical Oncology;2012, Vol. 4 Issue 3, p35 

    Fulvestrant, an estradiol analog that binds directly to the estrogen receptor (ER) and anastrozole, an inhibitor of the aromatase enzyme are two antiestrogen agents that are currently used in the endocrine treatment of postmenopausal women with breast cancer. This article reviews the clinical...

  • Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Cutrupi, S; Reineri, S; Panetto, A; Grosso, E; Caizzi, L; Ricci, L; Friard, O; Agati, S; Scatolini, M; Chiorino, G; Lykkesfeldt, A E; De Bortoli, M // Oncogene; 

    Pharmacological resistance is a serious threat to the clinical success of hormone therapy for breast cancer. The antiproliferative response to antagonistic drugs such as tamoxifen (Tam) critically depends on the recruitment of NCoR/SMRT corepressors to estrogen receptor alpha (ERα) bound to...

  • Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. Mattar, Andre; Logullo, Angela; Facina, Gil; Nonogaki, Suely; Soares, Fernando; Gebrim, Luiz // Journal of Cancer Research & Clinical Oncology;May2011, Vol. 137 Issue 5, p897 

    Purpose: The objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics